A Performance Comparison of Commonly Used Assays to Detect RET Fusions.

ABSTRACT:

Purpose

Selpercatinib and pralsetinib induce deep and durable responses in patients with advanced RET fusion-positive lung and thyroid cancer. RET fusion testing strategies with rapid and reliable results are critical given recent FDA approval. Here, we assess various clinical assays in a large pan-cancer cohort.

Experimental design

Tumors underwent DNA-based next-generation sequencing (NGS) with reflex to RNA-based NGS if no mitogenic driver or if a RET structural variant of unknown significance (SVUS) were present. Canonical DNA-level RET fusions and RNA-confirmed RET fusions were considered true fusions. Break-apart FISH and IHC performance were assessed in subgroups.

Results

A total of 171 of 41,869 patients with DNA NGS harbored

SUBMITTER: Yang SR 

PROVIDER: S-EPMC8285056 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature